Impact Factor 3.648 | CiteScore 3.99
More on impact ›

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Neurosci. | doi: 10.3389/fnins.2019.01016

Biomarkers in painful symptomatic knee osteoarthritis demonstrate that MRI assessed joint damage and type II collagen degradation products are linked to disease progression

 Nidhi Sofat1*, Vivian Ejindu2, Christine Heron2, Abiola Harrison1,  Soraya Koushesh1, Lena Assi1, Anasuya Kuttapitiya1, Guy Whitley1 and  Franklyn A. Howe1
  • 1St George's, University of London, United Kingdom
  • 2St George’s University Hospitals NHS Foundation Trust, United Kingdom

Background: Osteoarthritis (OA) is the most prevalent arthritis worldwide, but the evolution of pain in relation to joint damage and biochemical markers are not well understood. We evaluated the relation between clinical pain measures and evoked pain in relation to structural damage and biochemical biomarkers in knee OA.
Methods: A cross-sectional study in people with knee OA and healthy controls was conducted. A total of 130 participants with advanced OA requiring total knee replacement (TKR) (n=78), mild OA having standard care (n=42) and non-OA controls (n=6), with 4 drop-outs were assessed. Pain scoring was performed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC_P) and the Visual Analog Scale (VAS). Pain sensitisation was assessed by pain pressure thresholds (PPT). Knee MRI assessed joint damage using the MRI Knee Osteoarthritis Score (MOAKS). Overall MOAKS scores were created for Bone Marrow Lesions (BML), Cartilage Degradation (CD) and effusion/Hoffa synovitis (tSyn). Type II collagen cleavage products (CTX-II) were determined by ELISA.
Results: The advanced OA group had a mean age of 68.9 +/- 7.7 years and the mild group 63.1 +/-9.6. The advanced OA group had higher levels of pain, with mean WOMAC_P of 58.8 +/- 21.7 compared with the mild OA group of 40.6 +/-26.0. All OA subjects had pain sensitization by PPT compared with controls (p<0.05). WOMAC_P correlated with the total number of regions with cartilage damage (nCD) (R=0.225, p=0.033) and total number of BMLs (nBML) (R=0.195, p=0.065) using body mass index (BMI), age and Hospital Anxiety and Depression Scale (HADS) as covariates. Levels of CTX-II correlated with tSyn (R=0.313, p=0.03), nBML (R=0.252, p=0.019), number of osteophytes (R=0.33, p=0.002) and nCD (R=0.218, p=0.042), using BMI and age as covariates. A multivariate analysis indicated that BMI and HADS were the most significant predictors of pain scores (p<0.05).
Conclusion: People with both mild and advanced OA show features of pain sensitisation. We found that increasing MRI-detected joint damage was associated with higher levels of CTX-II, suggesting that increasing disease severity can be assessed by MRI and CTX-II biomarkers to evaluate OA disease progression.

Keywords: biomarkers, Pain - etiology, drug therapy, Sensitisation, magnetic resonance imaging, Arthritis

Received: 06 Jun 2019; Accepted: 06 Sep 2019.

Copyright: © 2019 Sofat, Ejindu, Heron, Harrison, Koushesh, Assi, Kuttapitiya, Whitley and Howe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Nidhi Sofat, St George's, University of London, London, United Kingdom,